PUBLICLY-TRADED CLINICAL LABORATORY COMPANIES released second quarter 2022 financial reports that confirmed a softening demand for COVID-19 tests, even as their base business revenues grew compared to last year. While continuing to address ongoing needs for SARS-CoV-2 testing, company leaders said during earnings calls that they are prioritizing the following business areas: Acquiring hospital laboratories. …
Public Laboratory Companies Eye More Lab Outreach Acquisitions Read More »
